Related references
Note: Only part of the references are listed.Genomics, epigenomics and pharmacogenomics of familial hypercholesterolemia (FHBGEP): A study protocol
Jessica Bassani Borges et al.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2021)
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial
John Rubino et al.
ATHEROSCLEROSIS (2021)
The Digenic Causality in Familial Hypercholesterolemia: Revising the Genotype-Phenotype Correlations of the Disease
Amina Kamar et al.
FRONTIERS IN GENETICS (2021)
Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report
Carolina Dagli-Hernandez et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting
Moeber Mahzari et al.
ADVANCES IN THERAPY (2021)
A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia
Julia Brandts et al.
ATHEROSCLEROSIS (2021)
Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use
Frank R. Wendt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations (vol 15, e0229098, 2020)
Mahtaab Hayat et al.
PLOS ONE (2021)
Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia
Lili Wang et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag
Bridget M. Kuehn
CIRCULATION (2021)
Saudi Familial Hypercholesterolemia Patients With Rare LDLR Stop Gain Variant Showed Variable Clinical Phenotype and Resistance to Multiple Drug Regimen
Zuhier Ahmed Awan et al.
FRONTIERS IN MEDICINE (2021)
Sudden Cardiac Death Caused by a Fatal Association of Hypertrophic Cardiomyopathy (MYH7, p.Arg719Trp), Heterozygous Familial Hypercholesterolemia (LDLR, p.Gly343Lys) and SARS-CoV-2 B.1.1.7 Infection
Nicola Marziliano et al.
DIAGNOSTICS (2021)
Variable and Severe Phenotypic Expression of the Lebanese Allele in Two Sisters with Familial Hypercholesterolemia
Johnny Chahine et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2021)
Management of Familial Hypercholesterolemia: Current Status and Future Perspectives
David T. W. Lui et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2021)
Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
Uma Ramaswami et al.
ATHEROSCLEROSIS (2020)
The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial
Rafael B. R. Leon-Cachon et al.
SCIENTIFIC REPORTS (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia The ODYSSEY HoFH Trial
Dirk J. Blom et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia A case report
Ane Bayona et al.
MEDICINE (2020)
Homozygous familial hypercholesterolemia with an update on cholesterol management
Anju J. J. Velvet et al.
OXFORD MEDICAL CASE REPORTS (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (vol 41, pg 111, 2019)
F. Mach
EUROPEAN HEART JOURNAL (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (vol 41, pg 111, 2019)
F. Mach
EUROPEAN HEART JOURNAL (2020)
A new variant (c.1A > G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition
Carmen Rodriguez-Jimenez et al.
ATHEROSCLEROSIS (2019)
Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene
Ana M. Bea et al.
ATHEROSCLEROSIS (2019)
LPA genotype is associated with premature cardiovascular disease in familial hypercholesterolemia
Martine Paquette et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink
Daniel F. Carr et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
Poulabi Banerjee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtitisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations
Paul N. Hopkins et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
I. K. Luirink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
Laurens F. Reeskamp et al.
ATHEROSCLEROSIS (2019)
Differential Responses to the PCSK9 Inhibitors, Evolocumab and Alirocumab, in a Patient with Heterozygous Familial Hypercholesterolemia: A Case Report
Michael Doyle
Journal of Clinical Lipidology (2018)
Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy
Annette M. Galema-Boers et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
Merel L. Hartgers et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab
Aurelie Thedrez et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Effects of 12weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin
Sergio Fazio et al.
CARDIOVASCULAR THERAPEUTICS (2018)
PCSK9 inhibitor therapy in homozygous familial defective apolipoprotein B-100 due to APOB R3500Q: A case report
Lars Andersen et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
A case of autosomal recessive hypercholesterolemia responsive to proprotein convertase subtilisin/kexin 9 inhibition
Eoin Francis Fahy et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy
Laura D'Erasmo et al.
ADVANCES IN THERAPY (2017)
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia
Hidenori Arai et al.
ATHEROSCLEROSIS (2016)
Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives
Claudia Sanna et al.
ATHEROSCLEROSIS (2016)
Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia
Frederick J. Raal et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up
Leopoldo Perez de Isla et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
John J. P. Kastelein et al.
LANCET (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels
Catherine E. de Keyser et al.
PHARMACOGENETICS AND GENOMICS (2015)
Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia
Valerie Leduc et al.
Pharmacogenetics and Genomics (2015)
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation
Hiroshi Mabuchi et al.
ATHEROSCLEROSIS (2014)
Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia
Paulo Caleb Junior Lima Santos et al.
ATHEROSCLEROSIS (2014)
The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia
Paulo C.J.L. Santos et al.
Pharmacogenetics and Genomics (2014)
POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia
Euridiki Drogari et al.
PHARMACOGENOMICS (2014)
Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments
Kenneth K. W. To et al.
PHARMACOGENOMICS (2014)
Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial
S. L. Charland et al.
PHARMACOGENOMICS JOURNAL (2014)
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Evan A. Stein et al.
CIRCULATION (2013)
Association of ANRIL polymorphism (rs1333049:C>G) with myocardial infarction and its pharmacogenomic role in hypercholesterolemia
Waqas Ahmed et al.
GENE (2013)
Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
Daniel I. Chasman et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2012)
Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia
Alexy Rosales et al.
CLINICA CHIMICA ACTA (2012)
The Lebanese allele at the LDLR in normocholesterolemic people merits reconsideration of genotype phenotype correlations in familial hypercholesterolemia
Akl C. Fahed et al.
ENDOCRINE (2012)
Diet, Genetics, and Disease: A Focus on the Middle East and North Africa Region
Akl C. Fahed et al.
JOURNAL OF NUTRITION AND METABOLISM (2012)
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)
Nelva Mata et al.
LIPIDS IN HEALTH AND DISEASE (2011)
Familial Hypercholesterolemia: The Lipids or the Genes?
Akl C. Fahed et al.
NUTRITION & METABOLISM (2011)
Combined Influence of LDLR and HMGCR Sequence Variation on Lipid-Lowering Response to Simvastatin
Lara M. Mangravite et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients
Miao Hu et al.
PHARMACOGENETICS AND GENOMICS (2010)
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER
Eliana Polisecki et al.
ATHEROSCLEROSIS (2008)
Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors
R. Alonso et al.
ATHEROSCLEROSIS (2008)
SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment
H. K. Berthold et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2008)
Quantitative effects of common genetic variations in the 3'UTR of the human LDL-receptor gene and their associations with plasma lipid levels in the Atherosclerosis Risk in Communities study
Hind Muallem et al.
HUMAN GENETICS (2007)
The association of common SNPs and haplotypes in the CETP and MDRI genes with lipids response to fluvastatin in familial hypercholesterolemia
D Bercovich et al.
ATHEROSCLEROSIS (2006)
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene - Long-term follow-up and treatment response
RP Naoumova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment
C Lahoz et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2005)
Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia
MC Vohl et al.
ATHEROSCLEROSIS (2002)
Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia
FH O'Neill et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Polymorphisms of the low-density lipoprotein receptor gene in Brazilian individuals with heterozygous familial hypercholesterolemia
LA Salazar et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2000)
A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP-493G/T) influences lipoprotein phenotype in familial hypercholesterolemia
B Lundahl et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
